Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Genentech taps Ribometrix for drugs that target RNA

by Ryan Cross
January 8, 2021 | A version of this story appeared in Volume 99, Issue 2

 

A computer model image of a small molecule (blue) binding to a pocket formed by three-dimensional folding of an RNA molecule (gray).
Credit: Ribometrix
A computer model of a small molecule (blue) binding to a pocket formed by three-dimensional folding of an RNA molecule (gray)

Genentech will collaborate with Ribometrix to discover and develop small molecules that target 3-D structures in RNA. Ribometrix was cofounded by Kevin Weeks, a chemist at the University of North Carolina at Chapel Hill, based on chemical-probing techniques he invented to determine the structures of RNA. The firm is one of several start-ups hoping to prove that small molecules can tackle RNA. It will earn $25 million up front and up to $1 billion in milestones.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.